share_log

Avenue Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Avenue Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Avenue Therapeutics | S-3：特定交易註冊聲明
美股sec公告 ·  05/07 00:47
牛牛AI助理已提取核心訊息
Avenue Therapeutics, Inc. (Avenue), a specialty pharmaceutical company, has filed a Form S-3 with the Securities and Exchange Commission (SEC) on May 3, 2024. The filing pertains to the registration of 1,420,741 shares of common stock underlying certain common warrants and placement agent warrants. These warrants were issued in connection with a private placement transaction that closed on May 1, 2024. The Series C and Series D Warrants, exercisable at $6.20 per share, and the Placement Agent Warrants, exercisable at $7.75 per share, are part of the registration. The Series C and Placement Agent Warrants are exercisable immediately and for a period of five years from the date of issuance, while the Series D Warrants are exercisable for eighteen months from issuance. The Selling Stockholders may sell...Show More
Avenue Therapeutics, Inc. (Avenue), a specialty pharmaceutical company, has filed a Form S-3 with the Securities and Exchange Commission (SEC) on May 3, 2024. The filing pertains to the registration of 1,420,741 shares of common stock underlying certain common warrants and placement agent warrants. These warrants were issued in connection with a private placement transaction that closed on May 1, 2024. The Series C and Series D Warrants, exercisable at $6.20 per share, and the Placement Agent Warrants, exercisable at $7.75 per share, are part of the registration. The Series C and Placement Agent Warrants are exercisable immediately and for a period of five years from the date of issuance, while the Series D Warrants are exercisable for eighteen months from issuance. The Selling Stockholders may sell the shares at any time after the effective date of the Registration Statement, through various methods including but not limited to brokerage transactions, block trades, and private sales. Avenue will not receive any proceeds from the sale of the shares by the Selling Stockholders but will receive proceeds from any cash exercise of the warrants. The common stock is listed on The Nasdaq Capital Market under the symbol 'ATXI'.
專業製藥公司Avenue Therapeutics, Inc.（Avenue）已於2024年5月3日向美國證券交易委員會（SEC）提交了S-3表格。該文件涉及某些普通認股權證和配售代理認股權證所依據的1,420,741股普通股的註冊。這些認股權證的發行與2024年5月1日完成的私募交易有關。C系列和D系列認股權證（可按每股6.20美元行使）和配售代理認股權證（每股7.75美元）是註冊的一部分。C系列和配售代理認股權證可立即行使，自發行之日起五年內行使，而D系列認股權證自發行之日起十八個月內可行使。賣出股東可以在註冊聲明生效之日後的任何時候通過各種方法出售股票，包括但不限於經紀交易、大宗交易和私人銷售。Avenue不會從出售股東出售股票中獲得任何收益，但將從認股權證的任何現金行使中獲得收益。普通股在納斯達克資本市場上市，股票代碼爲 “ATXI”。
專業製藥公司Avenue Therapeutics, Inc.（Avenue）已於2024年5月3日向美國證券交易委員會（SEC）提交了S-3表格。該文件涉及某些普通認股權證和配售代理認股權證所依據的1,420,741股普通股的註冊。這些認股權證的發行與2024年5月1日完成的私募交易有關。C系列和D系列認股權證（可按每股6.20美元行使）和配售代理認股權證（每股7.75美元）是註冊的一部分。C系列和配售代理認股權證可立即行使，自發行之日起五年內行使，而D系列認股權證自發行之日起十八個月內可行使。賣出股東可以在註冊聲明生效之日後的任何時候通過各種方法出售股票，包括但不限於經紀交易、大宗交易和私人銷售。Avenue不會從出售股東出售股票中獲得任何收益，但將從認股權證的任何現金行使中獲得收益。普通股在納斯達克資本市場上市，股票代碼爲 “ATXI”。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。